I am an ME/CFS patient and a clinician, and I’d prefer if Dr Brian Walitt were replaced as Lead Clinical Investigator of the proposed NIH study by a scientist who does not believe ME/CFS is somatoform.
Having reviewed a selection of Dr Walitt’s published papers from his NIH page
https://nccih.nih.gov/research/intramural/laboratory-clinical-investigations-branch/staff/walittb, his approach seems completely out of step with the 2015 Institute of Medicine report and the NIH’s own 2014 Pathways to Prevention report (
https://www.effectivehealthcare.ahrq.gov/ehc/products/586/2004/chronic-fatigue-report-150505.pdf, summary:
https://prevention.nih.gov/docs/programs/mecfs/ODP-P2P-MECFS-FinalReport.pdf.
Why is the Lead Clinical Investigator someone whose stated interest is somatoform illnesses?
Why is the Lead Clinical Investigator of an NIH study into “Post-Infectious ME/CFS” someone who does not believe that infection has been scientifically validated as a trigger for ME/CFS? In Wang, Walitt et al’s 2015 chemo-brain paper available at
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750385/, Walitt and his co-authors state
“Both of these illnesses [fibromyalgia and chronic fatigue syndrome] have disputed causal triggers, such as trauma in fibromyalgia and infection in chronic fatigue syndrome, whose validity is also not answered by the scientific literature to date.”
Why is the Lead Clinical Investigator instead someone who resists the biomedical research into the possibly related condition of fibromyalgia?
The following quotes are from Wolfe & Walitt’s 2013 paper entitled “Culture, science, and the changing nature of fibromyalgia”, available at
https://www.arthritis-research.org/... of fibromyalgia - NRR submission version.pdf Wessely, who will be familiar as a UK psychiatrist who espouses the somatoform theory of CFS, is cited a number of times by Wolfe & Walitt in this 2013 paper.
Wolfe & Walitt 2013: “Fibromyalgia's status as a 'real disease', rather than a psychocultural illness, is buttressed by social forces that include support from official criteria, patient and professional organizations, pharmaceutical companies, disability access, and the legal and academic communities.”
Wolfe & Walitt 2013: “The very strong resemblance of fibromyalgia to neurasthenia is a key observation. Time brings clarity to confusing illnesses of the past, and we now recognize that hysteria, neurasthenia and railway spine were almost always psychogenic disorders.”
Wolfe & Walitt 2013: “The rise of fibromyalgia and the disputes it has engendered represents the age-old battle over psychogenicity. All other things being equal, fibromyalgia should have failed. It began as a simple local pain disorder, but evolved over time in one that had multiple somatic symptoms and features that many considered psychosomatic. If these features were the death knell of neurasthenia, they should have also spelled the death of fibromyalgia. But they didn’t. The era was different, and powerful cultural forces stood being fibromyalgia and fought against the idea of a psychogenic illness.”
Wolfe and Walitt conclude: “Fibromyalgia seems to be a somatic symptom disorder with remarkable similarities to neurasthenia. It represents the end position on a continuum of distress. While psychological issues are clear, powerful societal forces are marshalled on behalf of fibromyalgia and it seems likely that they will sustain the fibromyalgia, at least for the present.”
[End of quotes by Wolfe and Walitt 2013]
In a 2014 paper written by Wolfe, Walitt and Hauser, entitled “What is fibromyalgia? How is it diagnosed, and what does it really mean?”, which appeared in the journal Arthritis Care and Research
http://onlinelibrary.wiley.com/doi/10.1002/acr.22207/epdf, similar views are put forward:
“Most fibromyalgia patients meet criteria for other functional somatic syndromes and psychological disorders, and we will find overlaps and comorbidity related to shared genetic and environmental factors…Knowledge of the broad quantity of PSD [polysymptomatic distress] over its entire severity spectrum, from mild to severe, enlightens patient care and provides a mechanism for assessment and understanding that can be more meaningful and effective than just casting about for a specific diagnosis.”
In the Wang, Walitt et al 2015 paper on chemobrain, further clarification is given that Walitt places chronic fatigue syndrome firmly in the same somatoform category where he places fibromyalgia: “The discordance between the severity of subjective experience and that of objective impairment is the hallmark of somatoform illnesses, such as fibromyalgia and chronic fatigue syndrome.”
ME/CFS urgently needs extensive biomedical research to elucidate pathophysiology and possible treatment pathways. Dr Walitt may indeed be interested in the potential of immunomodulatory drugs as possible future treatments, as am I, but this does not drown out his consistent description of chronic fatigue syndrome and fibromyalgia as somatoform/perceptual/psychogenic for me.
The key focus must be on research leading to improvement for patients. In the past 65-odd years, the somatoform theory of CFS has not yielded effective treatments for patients, despite the untenable claims of some researchers.
While I have not come across anything to suggest that Dr Walitt supports GET/CBT for ME/CFS, and it is my understanding that he does not promote their use in fibromyalgia, in his research Dr Walitt does consistently interpret a difference between what patients report and what he and his colleagues can measure as evidence of somatization. For example, see the 2014 paper entitled “Polysymptomatic distress in patients with rheumatoid arthritis: understanding disproportionate response and its spectrum”
http://onlinelibrary.wiley.com/doi/10.1002/acr.22300/epdf and the chemobrain paper. As a clinician I used cognitive assessments, and they are crude tools. The skill of the clinician in choosing the right tool for the right person and interpreting results appropriately is key. They only make sense alongside very individualised assessments of cognitive functioning within real-life settings. In my experience, there is often a gap between the actual level of impairment someone has and that “diagnosed” by a cognitive assessment, and I have never come across a case where somatization explained that gap.
Dr Walitt describes his research interests in this researcher story, dated August 2012 available at
http://georgetownhowardctsa.org/researchers/researcher-stories/brian-t--walitt-
Dr Walitt: “My research interest is perceptual illness. In these disorders, a person experiences a range of different bodily sensations, such as pain and fatigue, without any clear external cause. In some, these sensations can be bothersome while in others they can be disabling. The perceptual illnesses that interest me change their names with every generation, with current disorders being called fibromyalgia, chronic fatigue syndrome, and post-Lyme syndrome.”
Dr Walitt continues: “My involvement in the field started during my medical training as I saw my first patients with fibromyalgia. The complaints of these patients were very familiar and made me realize how common they are in the general population, even amongst my friends and family. The desire to figure out a way to alleviate this particular type of suffering drew me into the field. As I have become more involved in research over the years, I have become convinced that unraveling the mysteries of perceptual illnesses will also shed light into the mechanisms that enable all people to feel and think and expand our understanding of the human condition.”
The NIH study has great potential. The plans unveiled by Dr Avi Nath are, in my view, very promising. But I am concerned about the Lead Clinical Investigator’s belief that ME/CFS is somatoform/psychogenic. The PACE trial has demonstrated amply how researchers’ beliefs about an illness can affect patient selection, methodology, analysis and interpretation and cause great harm.
I would prefer a different Lead Clinical Investigator, someone who is not starting from an assumption that ME/CFS is somatoform.